Memphasys Limited

—As of Sun 8 Nov 2026, 12:00 UTC

ASX:MEMHealthcare

Country Australia

PE (Fwd) •••

TSR 10Y CAGR (18.87%)

Div yield —

ROE (95.94%)

Medical Devices

Beta (5Y) 0.76

PE TTM —

TSR TTM —

Mkt cap A$12.38M

ROIC (20.76%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

$0.0048

18.94%

(70.44%)

Sell 5|9|5|0|8

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

0.565

Revenue$M

1.369

1.448

1.516

1.649

1.793

1.932

2.114

2.312

2.462

2.654

0.595

8.17%

7.41%

41

17.30

Revenue growth%

7.12

5.52

6.13

6.53

3.80

6.18

7.19

9.80

10.47

10.48

22.41

9.80

6.83

66

19.92

Gross margin%

19.39

16.49

15.98

15.13

14.87

16.52

15.00

15.48

13.20

15.22

28.77

15.22

15.35

31

4.31

Operating margin%

23.51

26.26

26.21

27.66

24.86

24.44

21.98

20.17

18.47

19.54

7.75

20.17

23.98

16

4.58

Net margin%

9.17

10.71

9.07

11.13

12.81

9.93

9.91

9.23

8.57

7.56

27.55

9.23

9.57

83

9.015

P/E ratio (avg)x

10.36

11.57

12.14

13.17

14.73

17.34

19.98

19.73

19.74

21.85

18.17

19.74

16.04

22

27.54

EV/EBITx

13.14

15.24

15.05

15.57

16.45

19.62

21.26

23.00

27.07

31.60

27.95

23.00

18.04

62

10.70

FCF yield (avg)%

12.55

13.87

14.88

13.86

15.18

17.86

19.66

18.26

19.28

21.16

18.15

19.28

16.52

56

7.75

FCF margin%

15.69

13.18

10.93

12.35

14.98

15.27

17.72

15.06

15.11

14.10

12.09

15.11

15.02

60

1.453

FCF / Net incomex

1.987

1.938

2.124

2.310

2.189

2.387

2.528

2.794

3.149

3.198

1.013

2.794

2.349

32

25.42

ROIC%

5.91

8.08

6.16

7.15

5.61

7.35

8.72

5.89

8.89

6.38

9.92

7.35

6.76

62

29.44

Return on equity%

25.62

24.27

25.88

24.38

23.52

21.14

22.95

21.13

23.39

26.01

12.90

22.95

23.90

74

16.14

Return on assets%

0.40

3.19

4.18

2.33

1.62

0.40

3.34

3.05

2.16

4.57

7.67

3.05

2.69

34

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

0.34%

(0.68%)

—

26.98

EPS growth%

2.28

4.39

6.32

7.53

7.73

9.51

7.45

5.39

4.32

3.27

9.61

5.39

5.86

6

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

1.51%

4.33%

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

9.25%

9.19%

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

5.52%

1.46%

—

13.87

Div yield (avg)%

3.14

3.42

2.91

5.33

3.33

5.82

8.18

10.61

9.98

7.02

25.93

8.18

5.58

25

27.17

Payout ratio%

12.71

14.23

14.80

13.49

12.55

10.86

10.96

8.79

10.95

8.83

22.36

10.86

11.76

80

3.186

Shares (diluted)B

2.531

2.547

2.572

2.454

2.370

2.401

2.276

2.525

2.502

2.798

3.003

3.38%

1.12%

14

19.20

Buyback yield%

7.80

5.99

8.30

10.36

8.44

9.47

11.20

10.21

7.74

9.27

4.91

9.47

8.86

55

0.976

D/E ratiox

0.832

0.792

0.776

0.755

0.811

0.737

0.701

0.677

0.611

0.645

1.529

0.677

0.746

51

1.449

Enterprise value$M

0.258

0.261

0.264

0.229

0.251

0.263

0.268

0.235

0.235

0.229

0.366

(1.83%)

(0.47%)

66

1.157

LT debt$M

1.094

1.219

1.321

1.367

1.303

1.399

1.253

1.146

1.213

1.105

2.189

(3.25%)

0.27%

88

Peers (US$8.503M)

Cap (US$)

PE

Atomo Diagnostics…

9.297M

—

CurveBeam AI Limited

8.968M

—

ImpediMed Limited

7.546M

—

Milton Essex Spólka…

8.346M

—

Capital

TTM

5Y

10Y

Leveragex

0.939

0.078

0.075

EBIT/Intx

0.882

0.242

0.247

Own earn%

(275.63)

12.21

7.54

Sh yield%

33.07

17.73

15.49

Owners

Insiders/Inst%

7.78

49.83

Short interest%

2.93

SBC / revenue%

1.02

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

0

Op margin range%

18–28

$1 testx

0.0

Incr. ROIC%

9

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$2.654M

7.41%

1.00×

Cost of revenue

$1.305M

7.04%

0.97×

Operating expenses

$0.642M

8.02%

1.06×